Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Search Results: 1 - 2 of 2 matches for " Chavaboon Dechsukhum "
All listed articles are free for downloading (OA Articles)
Page 1 /2
Display every page Item
WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study
Wirote Netinatsunthorn, Jitti Hanprasertpong, Chavaboon Dechsukhum, Roengsak Leetanaporn, Alan Geater
BMC Cancer , 2006, DOI: 10.1186/1471-2407-6-90
Abstract: The study accrued women over an 18-year period, from 1987–2004. During the study period, 163 patients were diagnosed with advanced serous epithelial ovarian carcinoma and had undergone complete post-operative chemotherapy, but the final study group comprised 99 patients. The records of these women were reviewed and the paraffin-embedded tissue of these women stained with WT1 immunostaining. Survival analysis was performed using Kaplan-Meier and Cox regression methods.Fifty patients showed WT1 staining and forty-nine did not. Five-year survival of non-staining and staining groups were 39.4% and 10.7% (p < 0.00005); five-year recurrence-free survival of these groups were 29.8% and ≤ 7.5% (p < 0.00005), respectively. For survival the HR of WT1 staining, adjusted for residual tumor and chemotherapy response, was 1.98 (95% CI 1.28–3.79), and for recurrence-free survival the HR was 3.36 (95% CI 1.60–7.03). The HR for recurrence-free survival was not confounded by any other variables.This study suggests that expression of WT1 gene may be indicative of an unfavorable prognosis in patients with advanced serous epithelial ovarian carcinoma.Ovarian cancer is one of the leading problems in gynecologic malignancy in females worldwide. In Thailand, ovarian cancer is the sixth most common cancer among females, with approximately 1,655 new cases per year [1]. Although several histologic types of epithelial ovarian cancer exist, approximately 60% are of the serous epithelial type [2]. Due to their nonspecific initial symptoms, 70% of patients have widespread metastatic disease at the time of diagnosis [3]. Survival rate is generally low. Despite advances in evaluation and treatment, the survival rate for all stage of ovarian cancer has remained constant over the past 30 years [4]. Parameters such as International Federation of Gynecology and Obstetrics (FIGO) stage at diagnosis, histologic grade, cell type, and amount of residual disease after first surgery, represent the most impor
Anti-tumour activities of fucoidan from the aquatic plant Utricularia aurea lour
Dararad Choosawad,Ureporn Leggat,Chavaboon Dechsukhum,Amornrat Phongdara
Songklanakarin Journal of Science and Technology , 2005,
Abstract: Fucoidan, a sulfated polysaccharide with several biological activities, is usually isolated from marine seaweeds or from echinoderms. Here, we report on the anti-tumour activity of fucoidan isolated from the aquatic plant Utricularia aurea Lour (Lentibulariaceae). A crude extract (CE) prepared by incubating U.aurea with hot water at 95oC for 12 hr was partially purified by Sephadex G-50, eluting with a 50mM sodium acetate buffer, at pH 5.0, containing 0.5M NaCl. Partially purified fucoidan (PPF) had a 3- fold increase in fucose content when compared with the CE and a molecular weig t of 11.6 kDa as determined by Sephadex G-200. Chemical analysis showed that CE consisted of 62.5% glucuronic acid, 5.0% fucose, 1.7% sulfate and 12.0% proteins while PPF consisted of 65.0% glucuronic acid, 15.3% fucose, 2.1 % sulfate and 8.3% proteins.The anti-tumour activity of the CE and PPF was determined by the MTT test. The CE at 125 μg/mL fucoidan and PPF at 250 μg/mL inhibited the growth of KB cells (a nasopharynx tumour cell line), but did not inhibit that of normal fibroblast cells. The inhibition was postulated to occur via apoptosis as significantlymore apoptotic cells were found after treatment than in the untreated KB cells (P<0.05) by the TUNNEL (TdT-mediated dUTP Nick-End Labelling) assay.
Page 1 /2
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.